BIIB News and Press, Biogen Inc. From 01/22/24

2024-01-22 13:17:30 ET Summary Today, we take a deeper look at Sage Therapeutics, Inc., a biopharmaceutical company focused on developing brain health medicines. The stock has fallen sharply since June on a more limited FDA approval for the company's primary drug candidate. Th...

2024-01-20 10:00:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. With bond yields falli...

2024-01-19 12:42:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Easing financial condi...

2024-01-19 02:05:00 ET Summary ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Easing financial condi...

2024-01-17 17:32:22 ET Summary Alector, Inc. expects results from its phase 2 INVOKE-2 study, using AL002 for the treatment of patients with Alzheimer's disease, in Q4 of 2024. IND clearance received to begin a phase 2 study using AL101 for the treatment of patients with Alzheimer...

2024-01-11 08:15:15 ET More on Acorda Therapeutics Acorda Therapeutics, Inc. (ACOR) Q3 2023 Earnings Call Transcript Acorda Therapeutics, Inc. 2023 Q3 - Results - Earnings Call Presentation Acorda Therapeutics GAAP EPS of -$7.16, revenue of $27.72M Financial ...

2024-01-11 05:46:14 ET Biogen ( NASDAQ: BIIB ) and its Japanese partner Eisai ( OTCPK:ESALF ) have filed a marketing authorization application for their breakthrough Alzheimer's therapy, called Leqembi (lecanemab), in the EU. The application to the European Medicines Agency ...

Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China TOKYO and CAMBRIDGE, Mass., Jan 10, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclona...

2024-01-09 05:30:25 ET Biogen ( NASDAQ: BIIB ) and its Japanese partner Eisai ( OTCPK:ESALF ) announced on Tuesday market approval for their breakthrough Alzheimer's therapy, called Leqembi, in China. Leqembi (lecanemab), a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

2024-01-08 16:48:08 ET Biogen Inc. (BIIB) J.P. Morgan 42nd Annual Healthcare Conference January 08, 2024 02:15 PM EST Company Participants Chris Viehbacher - CEO Conference Call Participants Chris Schott - J.P. Morgan Presentation Chris Schott ...